Market Demand There is a significant market need for rapid, high-sensitivity diagnostic tests in emergency care, particularly for detecting heart attacks with results within 15 minutes, which current lab and point-of-care options do not fully address.

Innovative Technology Brava Diagnostics utilizes proprietary evanescent planar waveguide technology, enabling low-cost, high-margin consumables with lab-quality sensitivity at the point-of-care, creating a compelling value proposition for healthcare providers seeking faster and more accurate diagnostics.

Strategic Partnerships The merger with MBio Diagnostics and the backing of LightDeck Diagnostics suggest strong industry ties and technical expertise, providing potential leverage for expanding sales efforts in hospitals, emergency departments, and critical care units.

Funding & Growth With $4 million in initial funding and plans for clinical validation, Brava is positioned to accelerate product development and gain regulatory approvals, opening opportunities for early adopters in the critical care diagnostics market.

Target Customer Base Potential buyers include emergency physicians, hospital laboratories, and critical care units in large healthcare networks, where fast, accurate troponin testing can improve patient outcomes and streamline treatment decisions, presenting a substantial sales opportunity.